Vaheri A, Strandin T, Hepojoki J, Sironen T, Henttonen H, Makela S, Mustonen J. Uncovering the mysteries of hantavirus infections. Nat Rev Microbiol. 2013;11:539–50.
Article
CAS
PubMed
Google Scholar
Laenen L, Vergote V, Calisher CH, Klempa B, Klingstrom J, Kuhn JH, Maes P. Hantaviridae: current classification and future perspectives. Viruses. 2019;11:788.
Article
CAS
PubMed Central
Google Scholar
Avsic-Zupanc T, Saksida A, Korva M. Hantavirus infections. Clin Microbiol Infect. 2019;21S:e6–16.
Article
CAS
PubMed
Google Scholar
Lin XD, Guo WP, Wang W, Zou Y, Hao ZY, Zhou DJ, Dong X, Qu YG, Li MH, Tian HF, et al. Migration of Norway rats resulted in the worldwide distribution of Seoul hantavirus today. J Virol. 2012;86:972–81.
Article
CAS
PubMed
PubMed Central
Google Scholar
Jonsson CB, Hooper J, Mertz G. Treatment of hantavirus pulmonary syndrome. Antiviral Res. 2008;78:162–9.
Article
CAS
PubMed
Google Scholar
Jiang H, Du H, Wang LM, Wang PZ, Bai XF. Hemorrhagic fever with renal syndrome: pathogenesis and clinical picture. Front Cell Infect Microbiol. 2016;6:1.
CAS
PubMed
PubMed Central
Google Scholar
He J, Christakos G, Wu J, Cazelles B, Qian Q, Mu D, Wang Y, Yin W, Zhang W. Spatiotemporal variation of the association between climate dynamics and HFRS outbreaks in Eastern China during 2005–2016 and its geographic determinants. PLoS Negl Trop Dis. 2018;12:e0006554.
Article
PubMed
PubMed Central
Google Scholar
Balabanova Y, Gilsdorf A, Buda S, Burger R, Eckmanns T, Gartner B, Gross U, Haas W, Hamouda O, Hubner J, et al. Communicable diseases prioritized for surveillance and epidemiological research: results of a standardized prioritization procedure in Germany, 2011. PLoS ONE. 2011;6:e25691.
Article
CAS
PubMed
PubMed Central
Google Scholar
Schmaljohn CS. Vaccines for hantaviruses: progress and issues. Expert Rev Vaccines. 2012;11:511–3.
Article
CAS
PubMed
Google Scholar
Brocato RL, Hooper JW. Progress on the prevention and treatment of hantavirus disease. Viruses. 2019;11:610.
Article
CAS
PubMed Central
Google Scholar
Zhang YZ, Zou Y, Fu ZF, Plyusnin A. Hantavirus infections in humans and animals. China Emerg Infect Dis. 2010;16:1195–203.
Article
PubMed
Google Scholar
Yi Y, Park H, Jung J. Effectiveness of inactivated hantavirus vaccine on the disease severity of hemorrhagic fever with renal syndrome. Kidney Res Clin Pract. 2018;37:366–72.
Article
PubMed
PubMed Central
Google Scholar
Spearman P, Kalams S, Elizaga M, Metch B, Chiu YL, Allen M, Weinhold KJ, Ferrari G, Parker SD, McElrath MJ, et al. Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. Vaccine. 2009;27:243–9.
Article
CAS
PubMed
Google Scholar
Kimura T, Egawa S, Uemura H. Personalized peptide vaccines and their relation to other therapies in urological cancer. Nat Rev Urol. 2017;14:501–10.
Article
CAS
PubMed
Google Scholar
Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA, Kast WM, Fascio G, Marty V, Weber J. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res. 2000;6:3406–16.
CAS
PubMed
Google Scholar
van der Burg SH, Bijker MS, Welters MJ, Offringa R, Melief CJ. Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy. Adv Drug Deliv Rev. 2006;58:916–30.
Article
PubMed
CAS
Google Scholar
Perdomo-Celis F, Salvato MS, Medina-Moreno S, Zapata JC. T-cell response to viral hemorrhagic fevers. Vaccines (Basel). 2019;7:11.
Article
CAS
Google Scholar
Lindgren T, Ahlm C, Mohamed N, Evander M, Ljunggren HG, Bjorkstrom NK. Longitudinal analysis of the human T cell response during acute hantavirus infection. J Virol. 2011;85:10252–60.
Article
CAS
PubMed
PubMed Central
Google Scholar
Liu B, Ma Y, Zhang Y, Zhang C, Yi J, Zhuang R, Yu H, Yang A, Jin B. CD8low CD100- T cells identify a novel CD8 T cell subset associated with viral control during human hantaan virus infection. J Virol. 2015;89:11834–44.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ma Y, Cheng L, Yuan B, Zhang Y, Zhang C, Tang K, Zhuang R, Chen L, Yang K, Zhang F, Jin B. Structure and function of HLA-A*02-restricted hantaan virus cytotoxic T-cell epitope that mediates effective protective responses in HLA-A2.1/K(b) transgenic mice. Front Immunol. 2016;7:298.
PubMed
PubMed Central
Google Scholar
Ma Y, Wang J, Yuan B, Wang M, Zhang Y, Xu Z, Zhang C, Liu B, Yi J, Yang K, et al. HLA-A2 and B35 restricted hantaan virus nucleoprotein CD8+ T-cell epitope-specific immune response correlates with milder disease in hemorrhagic fever with renal syndrome. PLoS Negl Trop Dis. 2013;7:e2076.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ma Y, Yuan B, Zhuang R, Zhang Y, Liu B, Zhang C, Yu H, Yi J, Yang A, Jin B. Hantaan virus infection induces both Th1 and ThGranzyme B+ cell immune responses that associated with viral control and clinical outcome in humans. PLoS Pathog. 2015;11:e1004788.
Article
PubMed
PubMed Central
CAS
Google Scholar
Tang K, Cheng L, Zhang C, Zhang Y, Zheng X, Zhuang R, Jin B, Zhang F, Ma Y. Novel identified HLA-A*0201-restricted hantaan virus glycoprotein cytotoxic T-cell epitopes could effectively induce protective responses in HLA-A2.1/K(b) transgenic mice may associate with the severity of hemorrhagic fever with renal syndrome. Front Immunol. 2017;8:1797.
Article
PubMed
PubMed Central
CAS
Google Scholar
del Guercio MF, Alexander J, Kubo RT, Arrhenius T, Maewal A, Appella E, Hoffman SL, Jones T, Valmori D, Sakaguchi K, et al. Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo. Vaccine. 1997;15:441–8.
Article
PubMed
Google Scholar
Kashi VP, Jacob RA, Shamanna RA, Menon M, Balasiddaiah A, Varghese RK, Bachu M, Ranga U. The grafting of universal T-helper epitopes enhances immunogenicity of HIV-1 Tat concurrently improving its safety profile. PLoS ONE. 2014;9:e114155.
Article
PubMed
PubMed Central
CAS
Google Scholar
Chen Y, Yang D, Li S, Gao Y, Jiang R, Deng L, Frankel FR, Sun B. Development of a Listeria monocytogenes-based vaccine against hepatocellular carcinoma. Oncogene. 2012;31:2140–52.
Article
CAS
PubMed
Google Scholar
La Rosa C, Longmate J, Lacey SF, Kaltcheva T, Sharan R, Marsano D, Kwon P, Drake J, Williams B, Denison S, et al. Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis. 2012;205:1294–304.
Article
PubMed
PubMed Central
CAS
Google Scholar
Song L, Yang MC, Knoff J, Wu TC, Hung CF. Cancer immunotherapy employing an innovative strategy to enhance CD4+ T cell help in the tumor microenvironment. PLoS ONE. 2014;9:e115711.
Article
PubMed
PubMed Central
CAS
Google Scholar
Alexander J, Sidney J, Southwood S, Ruppert J, Oseroff C, Maewal A, Snoke K, Serra HM, Kubo RT, Sette A, et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity. 1994;1:751–61.
Article
CAS
PubMed
Google Scholar
Sun Y, Liu J, Yang M, Gao F, Zhou J, Kitamura Y, Gao B, Tien P, Shu Y, Iwamoto A, et al. Identification and structural definition of H5-specific CTL epitopes restricted by HLA-A*0201 derived from the H5N1 subtype of influenza A viruses. J Gen Virol. 2010;91:919–30.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhang J, Jia Z, Lin Z, Li J, Fu X, Huang Y, Zhao J, Nie L, Hou W, Yuan F, Wu Y. Computational prediction and experimental assessment of an HLA-A*0201-restricted cytotoxic T lymphocyte epitope from neutral endopeptidase. Immunol Res. 2012;52:231–9.
Article
CAS
PubMed
Google Scholar
Li H, Zhou M, Han J, Zhu X, Dong T, Gao GF, Tien P. Generation of murine CTL by a hepatitis B virus-specific peptide and evaluation of the adjuvant effect of heat shock protein glycoprotein 96 and its terminal fragments. J Immunol. 2005;174:195–204.
Article
CAS
PubMed
Google Scholar
Cheng L, Yu L, Wu X, Li K, Wang F, Zhang L, Ye W, Li P, Zhang F, Xu Z. Induction of specific humoral and cellular immune responses in a mouse model following gene fusion of HSP70C and Hantaan virus Gn and S0.7 in an adenoviral vector. PLoS ONE. 2014;9:e88183.
Article
PubMed
PubMed Central
CAS
Google Scholar
Yamada A, Sasada T, Noguchi M, Itoh K. Next-generation peptide vaccines for advanced cancer. Cancer Sci. 2013;104:15–21.
Article
CAS
PubMed
Google Scholar
Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer. 2008;8:351–60.
Article
CAS
PubMed
Google Scholar
Shen CM, Zhu BF, Ye SH, Liu ML, Yang G, Liu S, Qin HX, Zhang HD, Lucas R, Li SB. Allelic diversity and haplotype structure of HLA loci in the Chinese Han population living in the Guanzhong region of the Shaanxi province. Hum Immunol. 2010;71:627–33.
Article
CAS
PubMed
Google Scholar
La Rosa C, Wang Z, Brewer JC, Lacey SF, Villacres MC, Sharan R, Krishnan R, Crooks M, Markel S, Maas R, Diamond DJ. Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice. Blood. 2002;100:3681–9.
Article
PubMed
CAS
Google Scholar
Alexander J, del Guercio MF, Maewal A, Qiao L, Fikes J, Chesnut RW, Paulson J, Bundle DR, DeFrees S, Sette A. Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses. J Immunol. 2000;164:1625–33.
Article
CAS
PubMed
Google Scholar
Nezafat N, Ghasemi Y, Javadi G, Khoshnoud MJ, Omidinia E. A novel multi-epitope peptide vaccine against cancer: an in silico approach. J Theor Biol. 2014;349:121–34.
Article
CAS
PubMed
Google Scholar
Velders MP, Weijzen S, Eiben GL, Elmishad AG, Kloetzel PM, Higgins T, Ciccarelli RB, Evans M, Man S, Smith L, Kast WM. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J Immunol. 2001;166:5366–73.
Article
CAS
PubMed
Google Scholar
Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol. 2002;2:227–38.
Article
CAS
PubMed
Google Scholar
Tsunoda I, Sette A, Fujinami RS, Oseroff C, Ruppert J, Dahlberg C, Southwood S, Arrhenius T, Kuang LQ, Kubo RT, et al. Lipopeptide particles as the immunologically active component of CTL inducing vaccines. Vaccine. 1999;17:675–85.
Article
CAS
PubMed
Google Scholar
Arens R, Schepers K, Nolte MA, van Oosterwijk MF, van Lier RA, Schumacher TN, van Oers MH. Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+ T cell formation. J Exp Med. 2004;199:1595–605.
Article
CAS
PubMed
PubMed Central
Google Scholar
Castellino F, Germain RN. Cooperation between CD4+ and CD8+ T cells: when, where, and how. Annu Rev Immunol. 2006;24:519–40.
Article
CAS
PubMed
Google Scholar